FREQUENCY OF DOWN-REGULATION OF INDIVIDUAL HLA-A AND HLA-B ALLELES IN CERVICAL CARCINOMAS IN RELATION TO TAP-1 EXPRESSION

被引:150
作者
KEATING, PJ
CROMME, FV
DUGGANKEEN, M
SNIJDERS, PJF
WALBOOMERS, JMM
HUNTER, RD
DYER, PA
STERN, PL
机构
[1] PATERSON INST CANC RES, DEPT IMMUNOL, CRC, MANCHESTER M20 9BX, LANCS, ENGLAND
[2] FREE UNIV AMSTERDAM HOSP, INST PATHOL, 1081 HV AMSTERDAM, NETHERLANDS
[3] CHRISTIE HOSP NATL HLTH SERV TRUST, MANCHESTER M20 9BX, LANCS, ENGLAND
[4] ST MARYS HOSP, N W REG TISSUE TYPING LABS, MANCHESTER M13 0JH, LANCS, ENGLAND
关键词
CERVICAL CARCINOMA; TUMOR HLA CLASS 1; DOWN-REGULATION; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING; HUMAN PAPILLOMAVIRUS; IMMUNE SURVEILLANCE; TUMOR ESCAPE MECHANISM;
D O I
10.1038/bjc.1995.346
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The development of cervical carcinoma is strongly associated with specific types of human papillomaviruses (HPVs). A role for cellular immunity in cervical disease is supported by the increased occurrence of HPV-associated lesions in immunosuppressed individuals. Upon viral infection or malignant transformation, ensuing alterations in gene expression result in the generation of novel sets of peptides which can form complexes with specific HLA class I heavy chains and beta(2)-microglobulin. These are then expressed at the cell surface as potential targets for specific T cells. In this study of 100 carcinomas HLA-A and -B class I expression by the tumour cells was down-regulated at one or more alleles in at least 73% of cervical carcinomas. Interference with the transporter associated with antigen presentation (TAP), which translocates cytosolic peptides from endogenously synthesised proteins (e.g. viral) into the lumen of the endoplasmic reticulum was found in 38% of the HLA class I down-regulated tumours. Loss of expression for common HLA class I alleles ranged from 36% to 71%, and such changes might be expected to influence specific immunogenic peptide presentation and consequent immune recognition. These results underline the importance of single as well as multiple allelic loss in cervical neoplasia and have important implications for attempts to intervene immunologically in cervical cancer.
引用
收藏
页码:405 / 411
页数:7
相关论文
共 42 条
  • [1] PEPTIDE-INDUCED STABILIZATION AND INTRACELLULAR-LOCALIZATION OF EMPTY HLA CLASS-I COMPLEXES
    BAAS, EJ
    VANSANTEN, HM
    KLEIJMEER, MJ
    GEUZE, HJ
    PETERS, PJ
    PLOEGH, HL
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (01) : 147 - 156
  • [2] STRUCTURE OF THE HUMAN CLASS-I HISTOCOMPATIBILITY ANTIGEN, HLA-A2
    BJORKMAN, PJ
    SAPER, MA
    SAMRAOUI, B
    BENNETT, WS
    STROMINGER, JL
    WILEY, DC
    [J]. NATURE, 1987, 329 (6139) : 506 - 512
  • [3] NOMENCLATURE FOR FACTORS OF THE HLA SYSTEM, 1991
    BODMER, JG
    MARSH, SGE
    ALBERT, ED
    BODMER, WF
    DUPONT, B
    ERLICH, HA
    MACH, B
    MAYR, WR
    PARHAM, P
    SASAZUKI, T
    SCHREUDER, GMT
    STROMINGER, JL
    SVEJGAARD, A
    TERASAKI, PI
    [J]. TISSUE ANTIGENS, 1992, 39 (04): : 161 - 173
  • [4] AN EPSTEIN-BARR VIRUS-SPECIFIC CYTOTOXIC T-CELL EPITOPE IN EBV NUCLEAR ANTIGEN-3 (EBNA-3)
    BURROWS, SR
    SCULLEY, TB
    MISKO, IS
    SCHMIDT, C
    MOSS, DJ
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 171 (01) : 345 - 349
  • [5] LOSS OF MHC CLASS-I EXPRESSION IN CERVICAL CARCINOMAS
    CONNOR, ME
    STERN, PL
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1990, 46 (06) : 1029 - 1034
  • [6] DIFFERENCES IN MHC AND TAP-1 EXPRESSION IN CERVICAL-CANCER LYMPH-NODE METASTASES AS COMPARED WITH THE PRIMARY TUMORS
    CROMME, FV
    VANBOMMEL, PFJ
    WALBOOMERS, JMM
    GALLEE, MPW
    STERN, PL
    KENEMANS, P
    HELMERHORST, TJM
    STUKART, MJ
    MEIJER, CJLM
    [J]. BRITISH JOURNAL OF CANCER, 1994, 69 (06) : 1176 - 1181
  • [7] LOSS OF TRANSPORTER PROTEIN, ENCODED BY THE TAP-1 GENE, IS HIGHLY CORRELATED WITH LOSS OF HLA EXPRESSION IN CERVICAL CARCINOMAS
    CROMME, FV
    AIREY, J
    HEEMELS, MT
    PLOEGH, HL
    KEATING, PJ
    STERN, PL
    MEIJER, CJLM
    WALBOOMERS, JMM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (01) : 335 - 340
  • [8] DIMAIO D, 1991, ADV CANCER RES, V56, P133
  • [9] DUGGANKEEN M, 1994, PAPILLOMAVIRUS REP, V5, P3
  • [10] ELLIS JRM, 1995, IN PRESS NATURE MED, V1